Sitaxsentan for the treatment of pulmonary arterial hypertension.
Pulmonary arterial hypertension (PAH) is a life-threatening, progressive condition that eventually leads to right heart failure. Endothelin receptor antagonists (ETRAs) have been shown to be a safe and efficacious treatment for PAH. Sitaxsentan is a highly selective oral ETRA that, in clinical trials, has demonstrated significant improvements in exercise capacity, functional class and pulmonary hemodynamics in PAH. Sitaxsentan has been shown to be a well tolerated and effective agent with a durable response for the treatment of PAH, and is associated with a low incidence of liver toxicity.
Girgis
Reda E
RE
Johns Hopkins University, Division of Pulmonary & Critical Care Medicine, School of Medicine, 1830 E Monument St Fl 5, Baltimore, MD 21205-2100, USA. rgirgis@jhmi.edu
Dixon
Richard Af
RA